LIQUIDIA CORPORATION -

11,42

26-ноября-24 15:45:00

15 мин. задержка

Акции

+0,17

+1,51%

Сегодняшний диапазон

11,16 - 11,63

ISIN

N/A

Источник

NASDAQ

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 ноя 2024 05:30:00 Источник Nasdaq GlobeNewswire
Liquidia to Present at the Stifel 2024 Healthcare Conference

12 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024

06 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

04 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent

07 окт 2024 09:00:07 Источник Nasdaq GlobeNewswire
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

02 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

30 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

16 сен 2024 08:41:30 Источник Nasdaq GlobeNewswire
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

11 сен 2024 07:26:18 Источник Nasdaq GlobeNewswire
Liquidia to Present at Upcoming Investor Conferences

28 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

22 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

19 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

16 авг 2024 05:30:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 авг 2024 05:30:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

31 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

18 июн 2024 07:42:18 Источник Nasdaq GlobeNewswire
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

03 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

29 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 май 2024 16:43:14 Источник Nasdaq GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

10 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.